Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study
Authors:
- Toyohiro YamadaTYToyohiro Yamada
- Keita NakaneKNKeita Nakane
- Torai EnomotoTETorai Enomoto
- Masayuki TomiokaMTMasayuki Tomioka
- Tomoki TaniguchiTTTomoki Taniguchi
- Takashi IshidaTITakashi Ishida
- Kaori OzawaKOKaori Ozawa
- Kimiaki TakagiKTKimiaki Takagi
- Hiroki ItoHIHiroki Ito
- Shinichi TakeuchiSTShinichi Takeuchi
- Makoto KawaseMKMakoto Kawase
- Kota KawaseKKKota Kawase
Open Access
- 9 September 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (9) , 2243
Abstract
The treatment options are currently limited, and the oncological outcomes remain unclear, for patients with metastatic urothelial carcinoma (mUC) with or without third-line systemic therapy. We aimed to evaluate the oncological outcomes in real-world daily clinical practice after platinum-based chemotherapy followed by pembrolizumab for mUC. This retrospective, multicenter cohort study included patients with mUC who received second-line pembrolizumab in Japan. The patients were divided into the treatment group (those who received third-line treatment) and the BSC group (those who did not receive other treatments). The primary endpoint of this study was to evaluate the oncological outcomes. Of 126 patients enrolled in this study, 40 received third-line therapy. The median follow-up period was 8.0 months. The median overall survival (OS) times were nine months in the BSC group and 17 months in the treatment group (p < 0.001). The median progression-free survival (PFS) times were 4 months in the BSC group and 14 months in the treatment group (p < 0.001). In the multivariate analysis, performance status and liver metastasis were significantly associated with OS. Third-line therapy may have clinical potential advantages for improving the oncological outcomes in patients with mUC.Keywords
This publication has 21 references indexed in Scilit:
- Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death ( PD )‐1 or PD ligand 1 inhibitor therapyBJU International, 2016
- Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial CarcinomaEuropean Urology, 2016
- Third-Line Chemotherapy for Metastatic Urothelial CancerMedicine, 2015
- Gemcitabine Plus Nedaplatin as Salvage Therapy is a Favorable Option for Patients with Progressive Metastatic Urothelial Carcinoma After Two Lines of ChemotherapyAsian Pacific Journal of Cancer Prevention, 2015
- Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II studyMedical Oncology, 2013
- Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0Journal of the American Academy of Dermatology, 2012
- Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancerInternational Journal of Clinical Oncology, 2010
- Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy: Phase II—Results of EORTC Study 30986Journal of Clinical Oncology, 2009
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982